Kenvue Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KVUE in the last 30 days.
See all $KVUE insider activity →Kimberly-Clark (KMB) extended the expiration date for its exchange offers of Kenvue (KVUE) notes to November 2, 2026. The offers are part of Kimberly-Clark's pending acquisition of Kenvue, with up to $7B in new notes to be issued. The exchange is contingent on the acquisition's completion and other conditions.
Kenvue Inc. (KVUE) will release its Q3 2026 results on Oct. 30, 2026, before the market opens, but will not hold a conference call due to its pending transaction with Kimberly-Clark.
Kenvue, the maker of Tylenol and other consumer health products, will not hold a quarterly earnings call for its October 30 results due to its pending transaction with Kimberly-Clark. The company will release a press statement on its investor relations website. Kenvue is the world's largest pure-play consumer health company by revenue, with brands like Aveeno, BAND-AID, Johnson's, Listerine, and Neutrogena.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning KVUE (Kenvue Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent KVUE coverage spans mergers & acquisitions, corporate actions and financial news.
Extension gives KVUE note holders more time, may slightly support KVUE equity perception.
The no-call decision may reduce near-term management commentary, shifting focus to the earnings release itself and any deal-related disclosures bundled with results.
The skipped quarterly call suggests uncertainty or timing friction around the pending Kimberly-Clark transaction, which can keep investors cautious ahead of the Oct. 30 print.
The approval removes a key obstacle, supporting a positive re‑rating of the deal.
Kimberly-Clark (KMB) plans to issue $4.9B in senior notes to fund its acquisition of Kenvue, expected to close by Q4 2026. If the deal misses its 2027 deadline, KMB must redeem the notes at 101% of their value. The company also launched an exchange offer for Kenvue's existing notes.
AlphAI scores every news story that mentions KVUE with an AI model for sentiment and relevance, and aggregates insider trades from Kenvue Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kimberly-Clark (KMB) extended the expiration date for its exchange offers of Kenvue (KVUE) notes to November 2, 2026. The offers are part of Kimberly-Clark's pending acquisition of Kenvue, with up to $7B in new notes to be issued. The exchange is contingent on the acquisition's completion and other conditions.
2 min readKenvue Inc. (KVUE) will release its Q3 2026 results on Oct. 30, 2026, before the market opens, but will not hold a conference call due to its pending transaction with Kimberly-Clark.
2 min readKenvue, the maker of Tylenol and other consumer health products, will not hold a quarterly earnings call for its October 30 results due to its pending transaction with Kimberly-Clark. The company will release a press statement on its investor relations website. Kenvue is the world's largest pure-play consumer health company by revenue, with brands like Aveeno, BAND-AID, Johnson's, Listerine, and Neutrogena.
2 min readKimberly-Clark (KMB) received Chinese antitrust approval for its $40B acquisition of Kenvue (KVUE) on Oct. 10, following Brazil's approval. The deal is a major corporate transaction for both companies.
2 min readKimberly-Clark (KMB) plans to issue $4.9B in senior notes to fund its acquisition of Kenvue, expected to close by Q4 2026. If the deal misses its 2027 deadline, KMB must redeem the notes at 101% of their value. The company also launched an exchange offer for Kenvue's existing notes.
2 min readKenvue (KVUE) lost its appeal to overturn a ruling that revived 500 lawsuits claiming prenatal Tylenol exposure caused autism or ADHD. The court denied rehearing, allowing the cases to proceed. Kenvue disputes the claims and plans to seek Supreme Court review. The lawsuits allege acetaminophen increased developmental risks, though causation is unproven.
2 min readKimberly-Clark's stock rose 8% as it reported higher adjusted earnings and advanced in its $48.7B Kenvue acquisition. Q3 net sales were $4.134B, down from $4.150B a year ago. Adjusted EPS from continuing ops increased to $1.70 from $1.45. The company maintained its 2026 outlook, factoring in China's social-media disruptions. Final Q3 results are due Nov. 5.
2 min readKimberly-Clark is planning investor calls and considering a bond sale to help fund its $36B acquisition of Kenvue, which includes $6.7B in cash partly from new debt. The deal, supported by $7.7B in bridge loans from JPMorgan, is expected to close by year-end.
4 min readKimberly-Clark (KMB) is restructuring $7B of Kenvue (KVUE) debt to facilitate its $48B acquisition. The deal aims to avoid defaults and streamline capital structure. Kenvue's legal liabilities and market reaction are key considerations. The merger targets synergies and defensive consumer staples positioning. Regulatory and integration challenges remain.
3 min readKimberly-Clark's $48.7B acquisition of Kenvue received unrestricted approval from Brazil's competition authority following a planned divestiture of feminine-care products to Essity. The divestiture addressed overlap concerns.
2 min read
